Dr. Serhat Gumrukcu is the Executive Director and Director of Translational Research at Seraph Research Institute, based in Los Angeles, California. His research work in infectious and terminal diseases focuses on creating new approaches and mechanisms of actions in antiviral therapies for viruses including SARS-CoV-2, HIV, HBV, Influenza, and Ebola, as well as solid tumor cancers.
As a pioneering scientific researcher, Dr. Gumrukcu’s most recent breakthrough is a potential prevention and treatment for COVID-19 and Influenza using his signature Hijack RNA™ treatment strategy. The Hijack RNA™ strategy is a novel mechanism of action, initially invented by Dr. Gumrukcu in 2018, to target dozens of different viruses. Hijack RNA was shown to be effective against HBV, multiple strains of influenza viruses, and SARS-CoV-2 as well as other coronaviruses, with findings presented at several scientific conferences including the 2021 Conference on Retroviruses and Opportunistic Infections (CROI).
Dr. Gumrukcu completed his medical training at Dokuz Eylul University in 2004 in Izmir, Turkey, and went on to receive his medical degree (M.D.) at I.M. Sechenov Moscow Medical Academy/First Moscow State Medical University. He then completed two years of residency in Genetics at the same institution, receiving the Russian equivalent of a Ph.D. (formally recognized as such by the Turkish health and education ministries) for his residency training in the specialty of genetics. While continuing his medical research, he received a separate Ph.D. in Psychology (unrelated to his former medical practice overseas) from Ankara University in Turkey in 2010.
Well-respected for his innovative approach, Dr. Gumrukcu regularly collaborates with some of the world’s most influential research institutions and medical doctors.
Dr. Gumrukcu is a member of the American Society of Clinical Oncology (ASCO), International AIDS Society (IAS), HIV Medicine Association (HIVMA), The European Association for the Study of the Liver (EASL), and the American Society of Gene & Cell Therapy ASGCT) – where he serves on the Cancer Cell & Gene Therapy Committee and the Infectious Diseases and Vaccines Committee. He is also a guest lecturer at UCLA, and was recently selected to join the upcoming 2022 JP Morgan Founders Forum bringing together influential leaders from around the world.